Clinical Trials Logo

Ovarian clinical trials

View clinical trials related to Ovarian.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT02734004 Active, not recruiting - SCLC Clinical Trials

A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors.

MEDIOLA
Start date: March 17, 2016
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to look at the effectiveness, safety, and antitumor activity of study drugs MEDI4736 in combination with olaparib (modules 1, 2, 3, 4, 5 and 7) and MEDI4736 in combination with olaparib and bevacizumab (module 6). It will also examine what happens to the study drugs in the body and investigate how well the combination between MEDI4736, olaparib and bevacizumab is tolerated.

NCT ID: NCT01306032 Active, not recruiting - Fallopian Tube Clinical Trials

ABT-888 With Cyclophosphamide in Refractory BRCA-Positive Ovarian, Primary Peritoneal or Ovarian High-Grade Serous Carcinoma, Fallopian Tube Cancer, Triple-Negative Breast Cancer, and Low-Grade Non-Hodgkin s Lymphoma

Start date: January 2011
Phase: Phase 2
Study type: Interventional

Background: - The experimental cancer treatment drug ABT-888 works by preventing DNA repair in tumor cells. Cyclophosphamide is a cancer treatment drug that works by causing DNA damage in cells, including cancer cells, resulting in cell death. However, because cyclophosphamide has strong and unpleasant side effects, researchers are interested in finding drugs that can be given in combination with cyclophosphamide that will allow a lower dose of cyclophosphamide to be given with similar effects. The combination of ABT-88 and cyclophosphamide may be an effective treatment for some types of cancer, such as certain kinds of breast or ovarian cancer and non-Hodgkin s lymphoma that often do not respond to standard therapies. Objectives: - To evaluate the safety and effectiveness of ABT-888 and cyclophosphamide in ovarian and breast cancer and in non-Hodgkin s lymphoma that have not responded to standard treatments. Eligibility: - Individuals at least 18 years of age who have been diagnosed with (1) BRCA1/2 ovarian cancer, primary peritoneal or ovarian high-grade carcinoma, or fallopian tube cancer; (2) triple-negative breast cancer (not responsive to hormone-related therapy); or (3) low grade non-Hodgkin s lymphoma. Design: - Participants will be screened with a full medical history and physical examination, blood and urine tests, and tumor imaging studies. Participants will be divided into two groups with different treatment subgroups. - Group 1: Participants who have BRCA-positive ovarian cancer, primary peritoneal or ovarian high-grade serous carcinoma, or fallopian tube cancer - Participants will receive either the combination of ABT-888 and cyclophosphamide, or cyclophosphamide alone. - Participants will take the study drug by mouth once a day for 21-day cycles of treatment, and will keep a diary to record drug doses and any side effects. - Participants will have clinic visits with blood and urine tests, imaging studies, and other examinations on days 1, 2, 7, and 14 of cycle 1, and on the first day of all other cycles. - Group 2: Participants who have triple-negative breast cancer or non-Hodgkin s lymphoma - Participants will receive either the combination of ABT-888 and cyclophosphamide, or cyclophosphamide alone. - Participants will take the study drug by mouth once a day for 21-day cycles of treatment, and will keep a diary to record drug doses and any side effects. - Participants will have clinic visits with blood and urine tests, imaging studies, and other examinations on days 1, 2, 7, and 14 of cycle 1, and on the first day of all other cycles. - Participants receiving only cyclophosphamide who show signs of disease progression after tumor imaging studies can receive the combination of ABT-888 with cyclophosphamide. - Treatment will continue as long as participants tolerate the drugs and the disease does not progress.

NCT ID: NCT01078662 Active, not recruiting - Prostate Clinical Trials

Open Label Study to Assess Efficacy and Safety of Olaparib in Confirmed Genetic BRCA1 or BRCA2 Mutation Pats

Start date: February 21, 2010
Phase: Phase 2
Study type: Interventional

To assess the efficacy of oral olaparib in patients with advanced cancer who have a confirmed genetic BRCA1 and/or BRCA2 mutation, by assessment of tumour response